Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer.

导出 OA

翻译打印收藏纠错

作者： Elyssa,Denault ^[1] ; Erika,Nakajima ^[1] ; Vivek,Naranbhai ^[1] ; Jennifer A,Hutchinson ^[2] ; Lindsey,Mortensen ^[1] ; Elizabeth,Neihoff ^[1] ; Caroline,Barabell ^[1] ; Amy,Comander ^[1] ; Dejan,Juric ^[1] ; Irene,Kuter ^[2] ; Theresa,Mulvey ^[1] ; Jeffrey,Peppercorn ^[2] ; Aron S,Rosenstock ^[1] ; Jennifer,Shin ^[2] ; Neelima,Vidula ^[1] ; Seth A,Wander ^[2] ; Beverly,Moy ^[1] ; Leif W,Ellisen ^[2] ; Steven J,Isakoff ^[1] ; A John,Iafrate ^[2] ; Justin F,Gainor ^[1] ; Aditya,Bardia ^[2] ; Laura M,Spring ^[1]

作者单位： Massachusetts General Hospital, Boston, MA, USA. ^[1] Harvard Medical School, Boston, MA, USA. ^[2]

关键词 CDK4/6 inhibitor HER2+ breast cancer breast cancer hormone receptor-positive breast cancer triple-negative breast cancer

DOI 10.1177/17588359221119370

PMID 36051470

发布时间 2022-09-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Therapeutic advances in medical oncology

2022年14卷

17588359221119370页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

检索历史清除